Yehia Hashad's most recent trade in Bausch + Lomb Corp was a trade of 11,621 Common Shares, No Par Value done at an average price of $18.3 . Disclosure was reported to the exchange on Feb. 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 11,621 | 180,041 | - | 18.3 | 212,664 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 5,075 | 191,662 | - | 18.3 | 92,873 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.49 per share. | 26 Feb 2026 | 2,169 | 196,737 | - | 18.5 | 40,105 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 35,046 | 198,906 | - | 0 | Common Shares, No Par Value | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 29,406 | 163,860 | - | 0 | Common Shares, No Par Value | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2025 | 17,715 | 134,454 | - | 0 | Common Shares, No Par Value | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.32 per share. | 25 Jul 2025 | 2,841 | 116,739 | - | 14.3 | 40,683 | Common Shares, No Par Value |
| Unity Biotechnology Inc | Yehia Hashad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2025 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 60,085 | 60,085 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 25,225 | 119,580 | - | 0 | Common Shares, No Par Value | |
| Bausch + Lomb Corp | Hashad Yehia | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 2,751 | 94,355 | - | 17.8 | 49,050 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 2,324 | 97,106 | - | 17.8 | 41,437 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.53 per share. | 25 Jul 2024 | 2,841 | 99,430 | - | 15.5 | 44,121 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.47 per share. | 01 Mar 2024 | 2,143 | 102,271 | - | 16.5 | 35,295 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 63,516 | 63,516 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 20,973 | 104,414 | - | 0 | Common Shares, No Par Value |